Curriculum Vitae Dott. Gabai Andrea

Informazioni personali

Nome: Andrea Gabai

Nato il 13/08/1984

Abilitazione all’esercizio della professione e immatricolazione all’Ordine dei Medici Chirurghi e Odontoiatri di Udine 

Numero di matricola 05270

Profilo professionale

  • Medico Oculista presso la SOC di Oculistica dell’Azienda Sanitaria Universitaria Integrata di Udine – Ospedale S.Maria della Misericordia, Udine
  • Medico Oculista ambulatoriale presso Nuova Visione – Fondazione Banca degli Occhi del Veneto. Zelarino (Ve)
  • Medico Oculista ambulatoriale presso poliambulatorio FriulMedical, Prata di Pordenone (Pn)

Percorso studi

30/06/2011- 07/07/2016

Specializzazione in Oftalmologia (voto 110/110 e lode)

Dipartimento di scienze mediche e biologiche – Oftalmologia. Università degli studi di Udine, Italia

Tesi di specializzazione: ‘Efficacy and safety of trabeculectomy versus non-penetrating surgeries in open-angle glaucoma: a meta analysis’.


Ottobre 2003- 08/03/2010

Laurea in medicina e chirurgia (voto 110/110 e lode)

Università degli studi di Udine, Italia

Tesi di laurea: ‘Trattamento con bevacizumab nelle occlusioni venose retiniche’


Settembre 1998- Luglio 2003

Diploma di maturità scientifica

Liceo Scientifico “Giovanni Marinelli”, Udine, Italia


Esperienze formative e professionali

Agosto 2016

Internship clinica

Lumbini Eye Institute, Bhairahawa, Nepal


Marzo-Giugno 2016

Internship clinica

Ambulatorio Cornea, Fondazione Banca degli Occhi del Veneto (FBOV),

Zelarino (VE)


Luglio-Settembre 2013

Observership clinica

Manchester Royal Eye Hospital, Manchester, Regno Unito


Luglio-Agosto 2007

IFMSA Summer clerckship

Danderyd Hospital, Karolinska Institute, Stoccolma, Svezia


Settembre 2007- Agosto 2008

Progetto Erasmus

Charles University, Praga, Repubblica Ceca


Competenze professionali


Chirurgiche:

  • Facoemulsificazione di cataratta e impianto di IOL
  • Iniezioni intravitreali

Parachirurgia – laser:

  • Capsulotomia Nd:YAG laser
  • Iridotomia Nd:YAG laser
  • Trabeculoplastica laser selettiva
  • Fotocoagulazione retinica
  • Laser barrage

Pubblicazioni

Gabai A Veritti D, Lanzetta P. One-year outcome of ranibizumab for neovascular age-related macular degeneration: a thorough analysis in a real-world clinical

setting. Eur J Ophthalmol. 2014 May-Jun;24(3):396-401.

Gabai A, Veritti D, Lanzetta P. Fundus autofluorescence applications in retinal

imaging. Indian J Ophthalmol. 2015 May; 63(5):406–415.

Selective laser trabeculoplasty. Pignatto S, Veritti D, Gabai A, Lanzetta P. In:

Gunvant P, ed. Glaucoma – Current Clinical and Research Aspects. Rijeka: In Tech;

2011; 257-72.

Veritti D, Gabai A. Development of eye played key role in evolutionary advantage.

Ocular Surgery News Europe Edition. August 2011.

Veritti D, Gabai A. Updated guidelines on use of anti-VEGF alter treatment course for exudative AMD.

Ocular Surgery News Europe Edition. December 2011.

Gabai A, Veritti D. SLT may be a good first-choice treatment for glaucomatous eyes.

Ocular Surgery News Europe Edition. May 2012.

Lanzetta P, Brusini P, Gabai A. Documento di consenso sull’indicazione all’intervento di cataratta. In attachment to “Programmazione 2012 Contenimento dei tempi d’attesa Area Vasta Udinese – Criteri di eleggibilità e priorità per l’accesso all’intervento di rimozione di cataratta”.

August 2012.


Presentazioni a congressi

Lanzetta P, Veritti D. Gabai A. 12-month treatment with intravitreal ranibizumab for wet AMD in a “real world” clinical setting. Presented at “the Macula Society 34rth

Annual Meeting”; March 11, 2011; Boca Raton, FL, USA.

Gabai A, Veritti D, Lanzetta P. Ranibizumab in the treatment of neovascular AMD:

12 month result in a “real-worls” clinical setting. Presented at the Alpe-Adria 32nd

International Congress of Ophthalmology; May 13, 2011.

Veritti D, Gabai A, Lanzetta P. Trabeculoplastica laser selettiva: una review della

letteratura. Presented at the Annual Meeting of the “Società Italiana Laser in Oftalmologia”;

January 26, 2012; Cortina d’Ampezzo, Italy.

Veritti, A. Gabai, A. Augustin, F. Coscas, P. Lanzetta, A. Loewenstein, G.

Coscas.C linical signs and natural history: how to recognize inflammation in clinical practice? Presented at “The 3rd World Congress on Controversies in Ophthalmology” (COPHy)

March 24, 2012. Istanbul, Turkey.

Gabai A, Veritti D, Lanzetta P.Selective Laser Trabeculoplasty, 33rd International

Congress of Ophthalmology, Alpe Adria, June 29, 2012; Portoroz, Slovenia.

Gabai A, Menchini F, Lanzetta P. Terapia Steroidea dell’Edema Maculare.

Presented at the “Edema Maculare 2015” Meeting, May 29, 2015; Bassano del Grappa, Italy.

Gabai A, Veritti D, Lanzetta P . Risultati funzionali e morfologici dopo trattamento

con anti-VEGF della Proliferazione Angiomatosa Retinica, Presented at the Annual Meeting of the “Società Italiana Laser in Oftalmologia”;

January 31, 2014, Cortina D’Ampezzo, Italy.

Gabai A, Pignatto S, Lanzetta P. Dystichiasis Lymphedema Syndrome associated with optic disc coloboma and Morning Glory Syndrome. Presented at the annual meeting of “Società Italiana della Retina”

February 2015, Venice, Italy.

Ciccolo G, Gabai A, Lanzetta P. Vitrectomia 27 gauge con cannula d’infusione endoilluminata 25 gauge: la nostra esperienza. Presented at the “XVII Congresso Nazionale del Gruppo Italiano di Chirurgia Vitreoretinica (GIVRe)”;

June 16, 2016. Trieste, Italy.


Partecipazione a studi multicentrici

Non interventional retrospective study on social and economical impact of Diabetic

Macular edema. Novartis. (IMPACT DME) Role: sub-investigator.

A retrospective non-interventional study to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens with wet age-related macular degeneration. Bayer S.p.A. (AURA study – No impact: n. 15913). Role: sub-investigator.

Evaluation of the therapeutic equivalence of Travoprost PR and Travatan. Double

blind randomized clinical trial in subjects affected by glaucoma or intraocular hypertension. (Travoprost 01/2011. Eudract Nr. 2011-005419-10). Alcon.

Role: sub- investigator.

A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex® Versus Lucentis® in patients with Branch Retinal Vein Occlusion. Allergan. (COMO- MAF-AGN-OPH-RET-004. NCT Nr NCT01427751)

Role: OCT operator.

A 12-month, Randomized, Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5mg Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to VEGF-driven Choroidal Neovascularization

(MINERVA – CRFB002G2301). Fase III. Role: OCT operator.

A 24-month, Phase IIIb, Randomized, Double-masked, Multicenter Study Assessing the

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal

Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular

Age-related Macular Degeneration (OCTAVE – CRFB002A2405). Fase III.

Role: OCT operator.

A 12-month, Phase IIIb, Randomized, Visual Acuity Assessor-masked, Multicenter Study

Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen

Compared to Monthly Regimen, in Patients With Neovascular AMD (TREND – CRFB002A2411, NCT Nr . NCT01948830) Fase III. Role: Study coordinator.

A randomized, controlled study evaluating the efficacy and safety of RAnibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity RAINBOW(CRFB002H230). Fase III.

Role: sub-investigator.